Abstract 806P
Background
MBO is a severe complication of advanced cancer. An interprofessional ambulatory outpatient MBO program with nurse-led proactive call management was established to support patients (pts) with gynecologic cancers at Princess Margaret Cancer Centre, showing reduction of hospitalization needs and improved outcomes.
Methods
“My Bowels on Track” is a pilot ambulatory electronic monitoring program for pts with gynecologic cancers with or at risk of MBO. Educational materials, secure messaging systems and ≤13 questions (Q) are offered weekly/biweekly. Based on Q answers, an alerting system flags pts with symptoms (yellow and red alerts indicate moderate and high concern, respectively) and no response to Q. Pts are contacted by nurses following clinical or compliance alerts. The primary objective is to assess the adherence (≥70% Q completion considered adherent) on the first two months on the program. A secondary objective is to assess the sensitivity of the alerts to trigger recommendations. Adherence was calculated as a rate. Alert sensitivity was assessed with a generalized estimation equation.
Results
40 pts enrolled between 08/21 and 09/22. Median age was 64.5 years (range 29-79). Primary diagnosis was ovarian (75%), uterine (17.5%) or cervical (7.5%) cancer, and 92.5% of pts were on systemic therapy. Clinical/radiological active MBO was present in 30% and 12.5% of pts prior to and at enrollment, respectively. Median duration of the program was 55 days (range 8-121). The two-month adherence was 65% (95% CI 50-80%), and the overall adherence was 60% (95% CI 43-75%). 65 symptom related alerts (75% yellow; 25% red) were reported in 60% (24/40) of pts. There were 59 recommendations triggered by alerts (29% dietary, 22% laxatives, 20% clinic assessment, 16% other medication, 8% emergency department referral, 5% other). The sensitivity of the alerts to trigger actions was 72% (95% CI 58-82%).
Conclusions
This pilot electronic MBO monitoring program with real-time patient reported outcome assessment was feasible, with 65% adherence at two months. Based on questionnaire answers an alerting system flagged symptoms of concern in 60% of participants, with a high sensitivity to provide actions or recommendations as a response to alerts.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
ASCO Conquer Cancer Young Investigator Award (Ainhoa Madariaga).
Disclosure
A. Madariaga Urrutia: Financial Interests, Personal, Advisory Role: AstraZeneca, GSK, PharmaMar; Financial Interests, Personal, Invited Speaker: Clovis, AstraZeneca, GSK. N.C. Dhani: Financial Interests, Speaker, Consultant, Advisor: AstraZeneca, Merck. R. Grant: Financial Interests, Personal, Advisory Board: AstraZeneca, Eisai, Knight Therapeutics; Financial Interests, Personal, Other, Graduate scholarship: Pfizer; Non-Financial Interests, Advisory Role: Tempus, Incyte. V. Bowering: Financial Interests, Personal, Advisory Board: AstraZeneca; Non-Financial Interests, Personal, Advisory Board: GSK, AstraZeneca. A.M. Oza: Non-Financial Interests, Personal, Advisory Board: AstraZeneca, GSK, Clovis; Other, Personal, Research Funding: AstraZeneca, GSK, Clovis; Non-Financial Interests, Personal, Leadership Role: Ozmosis Research. A. Berlin: Other, Personal, Advisory Role: AbbVie, Ferring, Astellas Pharma. S. Lheureux: Financial Interests, Personal, Advisory Board: AstraZeneca, GSK, Eisai, Merck, Novartis; Financial Interests, Personal, Invited Speaker: GSK, Roche; Financial Interests, Institutional, Research Grant, Academic trial: GSK; Financial Interests, Institutional, Local PI: Repare Therapeutics, Merck, AstraZeneca, Regeneron, GSK, Roche, Seagen; Financial Interests, Institutional, Research Grant: Roche. All other authors have declared no conflicts of interest.
Resources from the same session
789P - Real-world (RW) duration of treatment in first-line maintenance (1Lm) niraparib monotherapy in epithelial ovarian cancer (EOC): CHAR1ZMA study
Presenter: Floor Backes
Session: Poster session 11
790P - Uniform prospective molecular analysis of endometrial carcinoma: Feasibility, outcomes, and effect on management
Presenter: Bradley Corr
Session: Poster session 11
791P - Development and validation of nomograms to predict survival in patients with high-grade serous ovarian cancer
Presenter: Xiaolian Peng
Session: Poster session 11
792P - Prognostic role of the modeled CA-125 KELIM in early FIGO stage I and II ovarian cancers (OC): A GCIG individual-patient data meta-analysis
Presenter: Pauline Corbaux
Session: Poster session 11
793P - Strong relationships between the CA-125 KELIM score and the tumor biological effects after neo-adjuvant chemotherapy in advanced ovarian cancer patients: CHIVA trial (GINECO)
Presenter: Ana Maria Catana
Session: Poster session 11
794P - Efficacy of gemcitabine (gem) based therapy in ovarian clear cell carcinoma (OCCC)
Presenter: Jerold Loh
Session: Poster session 11
795P - Tolerability and effectiveness of niraparib in long-term responders with platinum-sensitive recurrent ovarian cancer (GEICO-88R study)
Presenter: Juan Cueva Banuelos
Session: Poster session 11
796P - Initial management and long-term outcome of advanced low-grade serous ovarian cancer (LGSOC) exploring role of surgery and maintenance therapy in the French multicentre ESME database
Presenter: Thomas Papazyan
Session: Poster session 11
797P - Impact of consolidation cycles in predicting recurrence in patients treated with EMA-CO for high-risk gestational trophoblastic neoplasia
Presenter: Antoine DELEUZE
Session: Poster session 11
798P - Survival analysis of non-metastatic gestational choriocarcinoma (NMGCC) patients treated with chemotherapy
Presenter: Sakhr Alshwayyat
Session: Poster session 11